Exelixis Q2 2026 revenue $628.7M, GAAP EPS $0.82, non-GAAP EPS $0.91

EXELIXIS, INC.

Total revenues $628.7M, up 11% YoY; cabozantinib U.S. net product revenues $573.0M.
GAAP net income $212.1M ($0.82 diluted EPS) vs $184.8M ($0.65) in Q2 2025.
Non-GAAP net income $237.1M ($0.91 diluted EPS) vs $212.6M ($0.75) YoY.
R&D expenses $212.0M, SG&A $147.6M; both up YoY on clinical and marketing costs.
Zanzalintinib potential launch in metastatic colorectal cancer pending regulatory approval later 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.